SGLT2 inhibitor approved for broader heart failure population

Dapagliflozin (Forxiga) is the second SGLT2 inhibitor to be approved for patients with symptomatic chronic heart failure across the full spectrum of left ventricular ejection fraction (LVEF).

by Chloe Harman

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription and registration options.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us



  • Limited free articles a month 
  • Free email bulletins

Register Now

Take a 30-day trial

  • Join MIMS now and pay nothing for the first 30 days

Sign Up